Logical Assessment
Long/short equity, biotech, small-cap, micro-cap

An Incredibly Asymmetric Risk/Reward Ratio For Sanuwave Foreshadows Huge Upside

(Editors' Note:This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)

Understand The Process, Profit On Biotech

Needless to say, biotechs are a risky game to play. All too often, companies with what appear as compelling assets can have hundreds of millions of dollars in value evaporate over the course of a week following a series of unfortunate events. On the flip side, the potential for upside is massive.

Fortunately for investors looking to try their hand in the game, there is a structure to which almost all emerging biotechs conform. In its simplest form, it is the clinical pipeline- beginning with a preclinical asset that is taken through the three phases of clinical

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details